"Genetically Engineered Virus: A Promising Weapon Against Bladder Cancer"

CG Oncology, a startup led by Forbes 30 Under 30 alum Arthur Kuan, is developing a genetically engineered virus called CG0070 as a potential new treatment for bladder cancer. In clinical trials, the immunotherapy has shown promising results in bladder cancer patients who don't respond to other treatments, both alone and in combination with Merck's cancer drug Keytruda. CG Oncology recently raised $105 million in a financing round to support the development of the drug, which could be on the market as early as 2026. The company aims to supplant the current treatment for bladder cancer, which has remained largely unchanged since the 1970s.